Last reviewed · How we verify
BENZTROPINE MESYLATE
Benztropine mesylate is a marketed drug primarily indicated for the treatment of Parkinsonism. A key strength is its established presence in the market, with a key composition patent expiring in 2028, providing some protection against generics. The primary risk is the eventual loss of exclusivity post-2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | BENZTROPINE MESYLATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
- Parkinsonism
- Extrapyramidal Disorders
Common side effects
- Urinary retention
- Toxic psychosis
- Tachycardia
- Nausea
- Nervousness
- Numbness of fingers
- Listlessness
- Loss of appetite and weight
- Hyperthermia
- Heat stroke
- Exacerbation of pre-existing psychotic symptoms
- Dry mouth
Drug interactions
- phenothiazines
- haloperidol
- tricyclic antidepressants
Key clinical trials
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- CLOZAPINE Response in Biotype-1 (PHASE4)
- Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders (NA)
- Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder (PHASE4)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions (PHASE1)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions (PHASE1)
- A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection (PHASE2)
- Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BENZTROPINE MESYLATE CI brief — competitive landscape report
- BENZTROPINE MESYLATE updates RSS · CI watch RSS